| Methods |
Prospective, double‐blind, randomized, non‐inferiority trial |
| Participants |
92 volunteers were recruited through e‐mail lists with local and national distribution. The exclusion criteria were residence at > 1240 m, inability to complete a moderate hike at high altitude, younger than 18 years or older than 65 years, pregnant, having lived or slept at altitudes of > 1240 m in the preceding week, allergies to the study medications, or having ingested similar medicines or steroids in the preceding week |
| Interventions |
Ibuprofen (600 mg, 3 times daily, starting 4 hours before ascent) and visually identical placebo; or acetazolamide (125 mg, twice daily, started the night before ascent); or placebo |
| Outcomes |
The main outcome measure was acute mountain sickness incidence, using the Lake Louise Questionnaire (LLQ), with a score of > 3 with headache. Sleep quality and headache severity were measured with the Groningen Sleep Quality Survey (GSQS). |
| Notes |
Related to systematic review Nieto 2017
|
